Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis

Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis. In this article, we present the first case of a 45-year-old male patient with rheu...

Descripción completa

Detalles Bibliográficos
Autores principales: Erol, Kemal, Ertaş, Ragıp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788646/
https://www.ncbi.nlm.nih.gov/pubmed/33458669
http://dx.doi.org/10.46497/ArchRheumatol.2020.7541
_version_ 1783633071869788160
author Erol, Kemal
Ertaş, Ragıp
author_facet Erol, Kemal
Ertaş, Ragıp
author_sort Erol, Kemal
collection PubMed
description Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis. In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence.
format Online
Article
Text
id pubmed-7788646
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Turkish League Against Rheumatism
record_format MEDLINE/PubMed
spelling pubmed-77886462021-01-14 Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis Erol, Kemal Ertaş, Ragıp Arch Rheumatol Case Report Paradoxical psoriasis or psoriasiform lesion is an adverse effect, represented by the occurrence of a psoriasiform lesion or exacerbation of psoriasis caused by the drugs normally used for the management of psoriasis. In this article, we present the first case of a 45-year-old male patient with rheumatoid arthritis who developed psoriasiform lesions following treatment with tofacitinib, and highlight the possible pathogenetic mechanisms involved in such an occurrence. Turkish League Against Rheumatism 2019-10-11 /pmc/articles/PMC7788646/ /pubmed/33458669 http://dx.doi.org/10.46497/ArchRheumatol.2020.7541 Text en Copyright © 2020, Turkish League Against Rheumatism http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Report
Erol, Kemal
Ertaş, Ragıp
Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
title Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
title_full Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
title_fullStr Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
title_full_unstemmed Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
title_short Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis
title_sort tofacitinib induced psoriasiform lesion in a patient with rheumatoid arthritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788646/
https://www.ncbi.nlm.nih.gov/pubmed/33458669
http://dx.doi.org/10.46497/ArchRheumatol.2020.7541
work_keys_str_mv AT erolkemal tofacitinibinducedpsoriasiformlesioninapatientwithrheumatoidarthritis
AT ertasragıp tofacitinibinducedpsoriasiformlesioninapatientwithrheumatoidarthritis

Ejemplares similares